Omnicell provides automation and business analytics software for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. The company was founded in 1992 and is based in Mountain View, California.
OMCL Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for OMNICELL Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that OMNICELL Inc ranked in the 28th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for OMCL, they are:
The company's balance sheet shows it gets 99% of its capital from equity, and 1% of its capital from debt. Its equity weight surpasses that of 89.31% of free cash flow generating stocks in the Technology sector.
The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately just 6.27% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
OMCL's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 51.19% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Technology that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as OMCL, try INOD, BLKB, MIME, NXPI, and CCMP.
Omnicell (OMCL) has priced $500M of 0.25% convertible senior unsecured notes due September 15, 2025 (up 37.5% Conversion Premium) in a private placement. Initial purchasers of the notes will have an option to purchase up to an additional $75M notes. Closing date is September 25, 2020. Interest will be payable semi-annually in...
Omnicell (OMCL) has agreed to acquire Pharmaceutical Strategies Group’s ((PSG)) 340B Link business for $225M in cash.The acquisition expands Omnicell’ pharmacy supply chain capabilities for efficient, compliant management of 340B drug pricing program340B Link business posted annual revenues of ~$35MThe deal is expected to be immediately accretive to non- GAAP earnings per...